AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 232 min read$CLYM

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Original reporting
SEC EDGAR 8-K
Published Oct 23, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLYM
Bullish
high confidence
Mentioned
$CLYM
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLYMBullishHigh
01

Why it matters

The disclosed data provide the first human evidence of deep, durable APRIL suppression and significant Gd‑IgA1 reduction, supporting a Q12W dosing schedule and advancing the program toward Phase 2/3.

02

Market read

First‑time disclosure of promising early‑stage data for a niche renal disease therapy; likely to move CLYM shares and influence comparable biotech stocks.

03

What to watch

Regulatory feedback and the timeline to Phase 3 could delay commercialization, affecting valuation.

Relevance 8/10Novelty 9/10Timing: today

Background

Climb Bio (Nasdaq: CLYM) announced Phase 1 trial results for its anti‑APRIL antibody CLYM116/MIL116 at ASN Kidney Week 2026.

Company-level read

Ticker impact

$CLYMBullishHigh confidence
Context

Climb Bio disclosed Phase 1 data showing >90% APRIL suppression for 12 weeks and ~70% Gd-IgA1 reduction, supporting a Q12W dosing regimen.

Expected impact

upward pressure as investors price in the promising data and upcoming Phase 2 trial.

Evidence & confidence

First disclosure of robust pharmacodynamic data for a clinical-stage biotech; such news typically moves the stock sharply.

Market effects

Sector

May boost investor interest in renal‑focused biotech and antibody therapeutics.

Regional

Positive for US biotech sector, especially small‑cap clinical‑stage companies.

Global

Limited to niche therapeutic area but could attract global partnership interest.

Counterpoint

What could challenge this read

Data, while impressive, are from healthy volunteers; efficacy in patients remains unproven and could temper upside.

Key entities

  • company
    Climb Bio, Inc.

    Clinical‑stage biotech developing CLYM116/MIL116 for IgA nephropathy.

  • company
    Beijing Mabworks Biotech Co., Ltd.

    Partner holding rights to the program in Greater China.

Read at source← All news

Related articles

OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

markets.businessinsider.com3 min
OCT 20
$CLYMHigh

Why is Climb Bio stock surging today?

Climb Bio Inc. (CLYM) rose 10.9% after Deutsche Bank initiated coverage with a Buy rating and $28.00 target, citing its autoimmune drug pipeline. The bank noted recent valuation compression reflected sector-wide selloff, not company-specific issues. Multiple analysts maintain bullish ratings with targets up to $40, citing positive clinical data. Broader market gains and biotech sector stabilization also supported the move.

investing.com2 min
OCT 20
$CLYMHigh

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.

investing.com2 min
OCT 5
$CLYMHighAI 8/10

Raymond James reiterates Strong Buy on Climb Bio stock ahead of data

Raymond James maintained a Strong Buy rating and $34.00 price target for Climb Bio (NASDAQ:CLYM) after Phase 2 budoprutug data abstract release. The stock is up 453% over a year, trading at $10.94. Analysts' targets range from $18 to $40, with a consensus Strong Buy. Initial data shows safety and B cell depletion, with a full presentation expected on October 24. Recent Phase 1 trial results for CLYM116 also led to multiple analyst upgrades and higher price targets.

investing.com2 min